Molecular classification and pathogenesis of eosinophilic disorders: 2005 update

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• The term "idiopathic hypereosinophilic syndrome (HES)" previously indicated a poor understanding of eosinophilic disorder pathophysiology.
• Recent advancements in molecular biology and targeted therapies have revitalized the study of hypereosinophilia.

Purpose of the Study:

• To review molecular gains in myeloproliferative disorder (MPD)-type eosinophilias.
• To discuss classification and clinicopathological issues of hypereosinophilic syndromes (HES).

Main Methods:

• Analysis of recurrent genetic abnormalities in eosinophilic disorders.
• Identification of fusion tyrosine kinases and their role in myeloid disorders.
• Review of targeted therapies like imatinib.

Main Results:

• Recurrent molecular abnormalities, particularly fusion tyrosine kinases (e.g., PDGFRalpha/beta, FGFR1), are linked to eosinophilia-associated myeloid disorders.
• The FIP1L1-PDGFRA fusion defines a subset of HES and systemic mast cell disease as clonal eosinophilias.
• These findings support a semi-molecular classification of eosinophilic disorders.

Conclusions:

• Molecular discoveries have redefined previously heterogeneous eosinophilic disorders.
• Establishing the molecular basis of MPD-type eosinophilias is crucial for classification and treatment.
• Further research into the molecular pathophysiology of eosinophilic disorders is warranted.